Chi-Med Signs Collaboration With Lilly For Oncology, Inflammation Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal could be worth $29 million per candidate, Chi-Med CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
China IND Requirements Overly Burdensome To Industry – Shanghai R&D Summit
Speakers advocate lobbying Chinese government to relax requirements.
Merck KGaA Looks To Chinese Medicine For Oncology Candidates
Collaboration with China’s Chi-Med is part of an initiative to strengthen Merck’s natural compound expertise, exec tells “The Pink Sheet” DAILY.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee